Should you buy Beam Global (B beam) stock?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Global in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Beam Global stock. View analyst ratings for Beam Global or view top-rated stocks.
Is there a lot in there for beam?
So there should be a lot in there for Beam too. It is important to have better marketing and not just focus on government contracts. There is so much to do and the competition never sleeps. It would be a shame if January continued like December.
Where can I buy Beam Therapeutics stock?
Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Beam Therapeutics' stock price today?
When is Beam Global's next earnings release?
View analyst ratings for Beam Global or view top-rated stocks. When is Beam Global's next earnings date? Beam Global is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022. View our earnings forecast for Beam Global.
Why did the BEEM stock crash?
Revenue in the third quarter had fallen by 31% to $1.2 million, which Beam attributed to order delays related to COVID-19 and other delivery challenges.
Why is beam down?
To be sent to Earth via teleportation, as in stereotypical portrayals of aliens coming to Earth from their spaceship. This humorous phrase usually suggests that one is crazy.
Will Beam stock go up?
The 12 analysts offering 12-month price forecasts for Beam Therapeutics Inc have a median target of 92.50, with a high estimate of 145.00 and a low estimate of 38.00. The median estimate represents a +158.89% increase from the last price of 35.73.
Is beam a good stock to buy?
Out of 5 analysts, 2 (40%) are recommending BEAM as a Strong Buy, 2 (40%) are recommending BEAM as a Buy, 1 (20%) are recommending BEAM as a Hold, 0 (0%) are recommending BEAM as a Sell, and 0 (0%) are recommending BEAM as a Strong Sell. What is BEAM's earnings growth forecast for 2022-2024?
What does beam down mean?
phrasal verb. beam somebody down/up. (in science fiction stories) to transport somebody to or from a spaceship using special electronic equipment.
What does beam therapeutics do?
Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
Will CRSP stock go up?
Stock Price Forecast The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 112.00, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +59.77% increase from the last price of 70.10.
Is Beam Therapeutics publicly traded?
This is an initial public offering of shares of common stock of Beam Therapeutics Inc. We are selling shares of our common stock. The initial public offering price is expected to be between $ and $ per share. We have applied for listing of our common stock on The Nasdaq Global Market under the symbol BEAM.
Is beam a good long term investment?
However, an investment in BEAM is very risky as the whole industry is still at a very early stage. Therefore, while Beam is not a stock to "go all-in" for, it can be a great addition to almost anybody's portfolio....About BEAM.SymbolLast Price% ChgBEAM34.782.47%Oct 1, 2021
Does ARKG own beam?
ARKG Holdings of Beam Therapeutics (BEAM) - Updated Daily.
Should I buy or sell Beam Therapeutics stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 1 hold rating and...
What is Beam Therapeutics' stock price forecast for 2022?
6 analysts have issued 12 month price targets for Beam Therapeutics' stock. Their forecasts range from $62.00 to $152.00. On average, they expect B...
How has Beam Therapeutics' stock price performed in 2022?
Beam Therapeutics' stock was trading at $79.69 on January 1st, 2022. Since then, BEAM shares have decreased by 58.5% and is now trading at $33.08....
When is Beam Therapeutics' next earnings date?
Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Bea...
How were Beam Therapeutics' earnings last quarter?
Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings data on Monday, May, 9th. The company reported ($1.01) EPS for the quarter, t...
Who are Beam Therapeutics' key executives?
Beam Therapeutics' management team includes the following people: Mr. John M. Evans M.B.A. , CEO & Director (Age 44, Pay $1.02M) ( LinkedIn Prof...
What is 's approval rating as Beam Therapeutics' CEO?
1 employees have rated Beam Therapeutics CEO on Glassdoor.com . has an approval rating of 100% among Beam Therapeutics' employees. This puts in th...
Who are some of Beam Therapeutics' key competitors?
Some companies that are related to Beam Therapeutics include Qiagen (QGEN) , Qiagen (QGEN) , Neurocrine Biosciences (NBIX) , Repligen (RGEN) ,...
What other stocks do shareholders of Beam Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA) , A...
Should I buy or sell Beam Global stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Global in the last year. There are currently 1 buy rating fo...
What is Beam Global's stock price forecast for 2022?
1 analysts have issued twelve-month target prices for Beam Global's shares. Their forecasts range from $25.00 to $25.00. On average, they expect Be...
How has Beam Global's stock price performed in 2022?
Beam Global's stock was trading at $18.60 on January 1st, 2022. Since then, BEEM shares have decreased by 10.4% and is now trading at $16.67. View...
When is Beam Global's next earnings date?
Beam Global is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Beam Gl...
How were Beam Global's earnings last quarter?
Beam Global (NASDAQ:BEEM) released its earnings results on Tuesday, May, 24th. The company reported ($0.24) earnings per share for the quarter, mis...
Who are Beam Global's key executives?
Beam Global's management team includes the following people: Mr. Desmond Wheatley , Chairman, CEO, Pres & Sec. (Age 56, Pay $375k) ( LinkedIn Pr...
Who are some of Beam Global's key competitors?
Some companies that are related to Beam Global include nLIGHT (LASR) , Maxeon Solar Technologies (MAXN) , FTC Solar (FTCI) , Meta Materials (MM...
What other stocks do shareholders of Beam Global own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Global investors own include Tesla (TSLA) , Aimmune...
What is Beam Global's stock symbol?
Beam Global trades on the NASDAQ under the ticker symbol "BEEM."
What is a hold rating on beam?
What is the official website of beam global?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEEM, but not buy additional shares or sell existing shares.
What is the P/E ratio of beam global?
The official website for Beam Global is www.envisionsolar.com.
Is beam global a hold?
The P/E ratio of Beam Global is -32.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Who is beam global?
Wall Street analysts have given Beam Global a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beam Global wasn't one of them.
Does beam global pay dividends?
Beam Global engages in the invention, design, engineering, manufacture, and sale of solar powered products. It offers solar powered products and proprietary technology solutions for electric vehicle charging infrastructure, out of home advertising platforms, and energy security and disaster preparedness. The company was founded by Robert Lane Noble on June 12, 2006 and is headquartered in San Diego, CA.
When is beam conference 2021?
Beam Global does not currently pay a dividend.
Is beam 101 IND cleared?
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 1:00 p.m. ET . The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived
What is Stock Sentiment?
BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business and pipeline updates, as well as third quarter 2021 financial results. As part of today’s update, Beam announced that its Investigational New Drug (IND) application fo
More About Beam Therapeutics Inc
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
What is beam global?
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA.
Is Q3 revenue disappointing?
Beam Global has been added to the California Electric Vehicle Infrastructure Project (CALeVIP) EV charging program. Funded by the California Energy Commission (CEC) and implemented by the Center for Sustainable Energy (CSE), CALeVIP provides incentives for EV charger infrastructure and works with local partners to develop and implement projects that meet current and future regional EV needs. The statewide efforts aim to provide a streamlined process to fill the significant gaps in charging availability.
What is Stock Sentiment?
Q3 revenue is disappointing. I really like the product and believe they will sell a lot of units in the next few years. Path to profitability requires economies of scale . This is a long term investment.
What's Happening With BEAM Stock Today?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
More About Beam Therapeutics Inc
Beam Therapeutics Inc (BEAM) stock is up 2.79% while the S&P 500 is down -0.5% as of 11:03 AM on Thursday, Feb 10. BEAM has risen $1.91 from the previous closing price of $68.40 on volume of 308,374 shares. Over the past year the S&P 500 has gained 16.69% while BEAM is down -39.07%. BEAM lost $2.24 per share in the over the last 12 months.
What is beam global?
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA.
How many units did BEEM deliver in 2019?
BEEM’s primary product is the Electric Vehicle Autonomous Renewable Charger (EV ARC), which is effectively a carport with solar panels mounted on top. The EV ARC line includes a frame, panels, and battery to which a purchaser can connect an EV charger of their choice:
Does BEEM have a dramatic increase in revenues?
On a total unit basis, BEEM delivered 90 units in 2018, but just 65 in 2019, down 28% year over year. Even though the company has not provided clear unit delivery numbers YTD2020, revenues for the first nine months of 2020 are down 13%, making it safe to conclude that units are also down for the same period.
Is the management team well compensated?
There are two main indicators that suggest BEEM is unlikely to experience a dramatic increase in revenues. The first, and most significant, in our view, is the company’s backlog, which is typically a representation of orders to be delivered in the future.
Does New York City have a BEEM contract?
The management team is unusually well compensated. Between 2010 and 2019, the CEO + CFO compensation accounted for about 1/3 of cumulative revenues. The CFO was a senior finance executive at a company that had to restate its financials.